THE MOST THREATENING EGFR MUTATION
MAY BE THE ONE YOU DON’T SEE

Exon 20 insertion mutations in EGFR+ mNSCLC are more elusive and life-threatening than common EGFR mutations.1-10
These mutations differ from classical mutations, such as L858R and exon 19 deletions, in how they are detected and treated...
...leaving patients at risk of rapid disease progression on current targeted therapies.1-10

EGFR EXON 20 INSERTION MUTATIONS ARE THE 3RD MOST PREVALENT PRIMARY EGFR MUTATION, YET THEY ARE OFTEN UNDETECTED4

Current biomarker testing practices can make it difficult to identify these patients4,5,7,11

Your browser does not support SVG.

PCR-based tests, which are mutation-specific, have technical limitations and can only detect a limited number of exon 20 insertion mutations4,7,11

Your browser does not support SVG.

Exon 20 insertion mutations cannot be treated effectively with current targeted therapies. Therefore, they are not given prominence on the NGS report1,3,5-9

Through the use of testing techniques that detect a broader range of mutations—either liquid or tissue NGS—and careful examination of biomarker test results, you can better understand the full picture of treatment options for your patients with EGFR-positive mNSCLC.4,11,12

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) strongly advise broader molecular profiling in eligible patients with mNSCLC, with the goal of identifying rare driver mutations.13*

BUT ACCURATE DETECTION IS ONLY THE FIRST STEP IN FIGHTING THIS MUTATION

CURRENT TKI THERAPIES ARE NOT EFFECTIVE AT TREATING PATIENTS WITH EXON 20 INSERTION MUTATIONS, MAKING THEM MORE DIFFICULT TO TREAT THAN CLASSICAL EGFR MUTATIONS3,6-9

Exon 20 insertion mutations are intrinsically resistant to EGFR TKIs, unlike common sensitizing mutations (eg, L858R and exon 19 deletions) or EGFR exon 20 T790M mutations.3,6-9

Response to TKIs in treatment-naive patients:

Your browser does not support SVG.

EGFR exon 20 insertion mutations14,15

Your browser does not support SVG.

EGFR exon 20 insertion mutations10

Your browser does not support SVG.

Classical EGFR exon 19 deletion or L858R mutation16

Results from a real-world analysis of treatment patterns (95% confidence interval [CI], 2.8-19.4).10

§The median overall survival was 38.6 months (95% CI, 34.5 to 41.8) in the osimertinib group and 31.8 months (95% CI, 26.6 to 36.0) in the comparator group (hazard ratio for death, 0.80; 95.05% CI, 0.64 to 1.00; P=0.046).16

The NCCN Guidelines® recommend treating patients without a sensitizing EGFR mutation, like patients with most exon 20 insertion mutations, with a systemic therapy, like platinum-based chemotherapy.13¶

Progression-free survival in treatment-naive patients with exon 20 insertion mutations:

Your browser does not support SVG.

Platinum-based chemotherapy17-19

Your browser does not support SVG.

TKIs3||

||TKIs included in this analysis were erlotinib, gefitinib, and afatinib.3

DON’T LET THIS MUTATION GET BY YOU. TEST FOR, FIND, AND APPROPRIATELY MANAGE EXON 20 INSERTION MUTATIONS.

YOUR PATIENTS’ LIVES DEPEND ON IT

SIGN UP TO RECEIVE THE LATEST INFORMATION REGARDING EXON 20 INSERTION MUTATIONS

First Name*

Last Name*

Email*

ZIP

*Required field

The information you provide will only be used by Janssen Pharmaceuticals, Inc., our affiliates, and our service providers to provide you information about mNSCLC, including Janssen products, services, and programs relating to mNSCLC. You may request to be removed from our contact list by calling 1-800-JANSSEN (1-800-526-7736). Our Privacy Policy further governs the use of the information you provide. By providing your information and selecting the "Sign up" button, you indicate that you read, understand, and agree to these terms.

Loading
Your message has been sent. Thank you!